Regenxbio has guided its Duchenne muscular dystrophy gene therapy candidate through another test, reporting a clean safety profile and functional improvements as it heads toward pivotal data.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Regenxbio has guided its Duchenne muscular dystrophy gene therapy candidate through another test, reporting a clean safety profile and functional improvements as it heads toward pivotal data.